

May 17, 2021 NIPRO CORPORATION



Acquisition of Shares of a Pharmaceutical Glass Container Manufacturing and Sales Company by a Nipro Overseas Subsidiary

Nipro Corporation (Main Office: Kita-ku, Osaka; President & Representative Director: Sano Yoshihiko) hereby announces that its overseas subsidiary Nipro PharmaPackaging International N.V. (Head Office: Belgium; Representative: Stephan Arnold; hereinafter "NPI") has acquired all issued shares in Piramida d.o.o (Head Office: Republic of Croatia; Representative: Kresimir Sečak), a company that manufactures and sells pharmaceutical glass containers, and has turned Piramida into a subsidiary.

1. Purpose for acquiring shares

With many global companies including major healthcare companies as customers, Piramida has established an outstanding market position in Central Europe as a pharmaceutical glass container (ampoules, vials) manufacturing and sales company. Nipro's PharmaPackaging Business operates in western Europe, with core manufacturing bases in France and Germany. Through the acquisition of Piramida, Nipro will be able to foray into unexplored markets and expand its market share throughout Europe. Through this share acquisition, NPI aims to improve its price competitiveness and further strengthen its stable supply system by vigorously reviewing the product portfolio of its existing manufacturing bases. Piramida will change its name to Nipro Pharmapackaging Croatia d.o.o.

2. Overview of share acquisition

- (1) Date of acquisition: April 30, 2021
- (2) Type and number of shares acquired: One (1) share of common stock (equivalent to all issued shares)

3. Overview of the company from which shares were acquired

- (1) Company name: Piramida d.o.o.
- (2) Representative: Kresimir Sečak
- (3) Location: Zagreb, Republic of Croatia
- (4) Established: 1950
- (5) Business: Manufacture and sales of pharmaceutical glass containers (ampoules and vials)
- (6) Sales: 103,187,000 kuna (fiscal year ending December 2020)
- (7) Capital: 26,319,500 kuna
- (8) Number of employees: 193 (as of December 2020)



4. Impact on business results

The impact of the share acquisition on the business results for the current fiscal year (ending March 2022) is expected to be immaterial.

